Amgen Inc. Q3 2025 Earnings Recap

AMGN Q3 2025 November 6, 2025

Get alerts when AMGN reports next quarter

Amgen reported strong Q3 2025 earnings with a 12% year-over-year revenue increase to $9.6 billion, driven by robust volume growth across all therapeutic areas and significant pipeline advancements.

Earnings Per Share Beat

$5.64 vs $5.02 est.

+12.4% surprise

Revenue Beat

9557000000 vs 8966454611 est.

+6.6% surprise

Market Reaction

1-Day +1.46%

5-Day +6.47%

30-Day -0.55%

See AMGN alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue growth of 12% year-over-year, with volume up 14%, highlighting strong product demand.
Six key growth drivers, including Repatha and EVENITY, contributed significantly, with annual sales of 14 products exceeding $1 billion.
Non-GAAP operating margin maintained at 47%, supported by a 31% increase in R&D investment to enhance late-stage pipeline prospects.
Launch of AmgenNow platform facilitates broader patient access to Repatha at competitive prices.
Strong performance in biosimilars, with revenues up over 50% year-over-year, now annualizing at approximately $3 billion.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit AMGN on AllInvestView.

Next Q1 2026